US · Healthcare · Biotechnology
EPS came in at 0.85 against a street estimate of 0.79 — a beat of 7.6%.
Analysts rate Exelixis Inc a buy (7 buy, 10 hold, 1 sell out of 18) with an average price target of $61.36.
CONFIDENT Exelixis reported strong Q3 growth, with CABOMETYX revenue up 12% year over year and zanzolintinib advancing toward multiple potential oncology indications. Q3 FY26 Worldwide cabozantinib franchise revenue generated by Exelixis and partners was approximately $818 million, up about 11% year over year. Analysts focused on 340B exposure, CABOMETYX demand, RCC opportunities, CRC commercialization and zanzolintinib trial expectations. Management emphasized limited 340B impact, strong cabo momentum and broad franchise potential while avoiding detailed speculation on ongoing studies. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.92% |
| Farallon Capital Management, L.L.C. | 5.52% |
| Renaissance Technologies Corp | 5.50% |
| Vanguard Portfolio Management, LLC | 4.94% |
| AQR Capital Management LLC | 4.52% |
| Vanguard Capital Management, LLC | 4.49% |
| State Street Corp | 4.09% |
| Fuller & Thaler Asset Management Inc | 3.66% |
| Document | Date |
|---|---|
| Quarterly report · Q3 FY2027 HEADLINE NUMBERS • Q3 2026 total revenue was $658.696 million, up from $597.755 million in Q3 2025. • Nine-month 2026 revenue was $1.898198 billion, | 2026-10-29 |
| Results announced · Q3 FY2027 HEADLINE NUMBERS • Q3 2026 total revenue was $658.7 million, up from $597.8 million in Q3 2025. • Net product revenue was $604.9 million, up from $5 | 2026-10-29 |
| Company announcement · Q3 FY2027 EXELIXIS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Drug under review: Zanzalintinib in combination with atezolizumab for metastatic colorectal can | 2026-09-11 |
| Company announcement · Q3 FY2027 EXELIXIS, INC. - FORM 8-K SUMMARY Date of Report: August 31, 2026 --- HEADLINE NUMBERS • U.S. Court of Appeals for the Federal Circuit affirmed tha | 2026-08-31 |
| Quarterly report · Q2 FY2027 EXELIXIS, INC. — Q2 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Q2 2026 Net Income: $212.0 million (vs. $184.8 million in Q2 2025, +14.7%) • H1 2026 N | 2026-08-05 |
| Results announced · Q3 FY2027 EXELIXIS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Total Revenues Q2 2026: $628.7 million vs. $568.3 million in Q2 2025 (up 10.6%) • Net | 2026-08-05 |
| Board / officer change · Q2 FY2027 EXELIXIS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held May 26, 2026 via live webcast • 11 directors elected to serve until 2027 an | 2026-05-29 |
| Quarterly report · Q1 FY2027 EXELIXIS, INC. — Q1 2026 (10-Q) SUMMARY HEADLINE NUMBERS • Net income Q1 2026: $210.5 million vs $159.6 million Q1 2025 (+32%) • Diluted EPS Q1 2026 | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Board authorizes $750 million stock repurchase program through December 2027 Exelixis, a pharmaceutical company, reported its Q2 2026 financial results on May 5, 2026. While the 8-K filing itself doesn't include specific financial figures (those are in the attached p | 2026-05-05 |
| FY2026 preliminary results and FY2027 financial guidance provided Exelixis, Inc. announced preliminary unaudited financial results for the fiscal year ended January 2, 2026, along with guidance for the next fiscal year (ending January 1, 2027) on January 1 | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Exelixis Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.